




RealRate

PHARMACEUTICAL 2015

Immune Design CORP
Rank 79 of 274



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2015

Immune Design CORP Rank 79 of 274

The relative strengths and weaknesses of Immune Design CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Design CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Immune Design CORP is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 339%, being 85% points above the market average of 254%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	77,982	Assets	78,383
Cost of Goods Sold	0	Liabilities	11,947
Intangible Assets	0	Expenses	36,311
Liabilities, Current	11,947	Revenues	6,433
Liabilities, Non-Current	0	Stockholders Equity	66,436
Other Assets	0	Net Income	-29,878
Other Compr. Net Income	0	Comprehensive Net Income	-29,878
Other Expenses	638	BaseVar	66,537
Other Liabilities	0	ECR before LimitedLiability	255%
Other Net Income	0	Economic Capital Ratio	339%
Other Revenues	6,433		
Property and Equipment	401		
Research and Development	22,746		
Selling, General and Administrative Expense	12,927		